Cached Profile

GENERAL EP

Active Ingredients (Generic):Unmapped

Therapeutic Area: THERAPIES

LIFETIME PROMOTIONAL SPEND

$68

General Payments Aggregated (2021–2024)

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

FDA Patient Safety Profile

Dynamic safety indicators compiled from official FDA product labels.

Active Clinical Trials

Clinical studies listing this drug as an active intervention.

Optimal Timing Trial: Randomized Trial of Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

ACTIVE_NOT_RECRUITINGPhase NANCT01943695

Pharmacodynamic Response to Exercise Treatment and Plant-Based Diet in Overweight/Obese Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer: A Phase 2 Randomized Control Trial

ACTIVE_NOT_RECRUITINGPhase PHASE2NCT04298086

Effectiveness of Virtual Bodily Illusion Intervention in Upper Limb Motor Function, Sensibility and Pain in People With Incomplete Spinal Cord Injury.

UNKNOWNPhase NANCT05142943

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients

COMPLETEDPhase PHASE3NCT01870024

Comparison of Postoperative Analgesic Effectiveness of Erector Spinae Plane Block and Combined With Superficial Parasternal Intercostal Plane Block Within the Enhanced Recovery After Cardiac Surgery (ERACS) Program: A Prospective, Randomized, Double-Blind Study

COMPLETEDPhase NANCT07304635

Top Funded Physicians (Cumulative)

Doctors receiving the highest aggregate promotional support for this product.

Dr. GEORGE HEBERTONMedical Doctor$23

Dr. AUSTIN HOWARDMedical Doctor$23

Dr. MOHAMMAD SAEEDMedical Doctor$23

Drug Marketing Payments Log

Federal registry records of promotional speaking, consulting, meals, and offsets.

Year:

2024

Filter < $250

Querying Open Payments Database

Fetching live CMS.gov records for GENERAL EP...